Simplex Trading
ARQT icon

Simplex Trading’s Arcutis Biotherapeutics ARQT Stock Holding History

Simplex Trading’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,795
Closed -$233K – 8722
2024
Q1 		$255K Sell
25,795
-30,023
-54% -$224K ﹤0.01% 4583
2023
Q4 		$180K Buy
+55,818
New +$152K ﹤0.01% 4778
2022
Q4 		– Sell
-711
Closed -$12.4K – 9142
2022
Q3 		$13K Sell
711
-16,274
-96% -$369K ﹤0.01% 7958
2022
Q2 		$361K Buy
16,985
+15,177
+839% +$311K ﹤0.01% 3859
2022
Q1 		$34K Buy
1,808
+1,666
+1,173% +$28.2K ﹤0.01% 7623
2021
Q4 		$2K Buy
+142
New +$2.83K ﹤0.01% 9954
2021
Q2 		– Sell
-29
Closed -$817 – 9987
2021
Q1 		$0 Buy
+29
New +$906 ﹤0.01% 8742

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading's ARQT Position: Q2 2024 in Review

Simplex Trading sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 25,795 shares — an estimated $233K sold.

Simplex Trading first reported a position in ARQT in Q1 2021 and held it in 7 quarters. The position peaked at $361K in Q2 2022. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • Simplex Trading reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Simplex Trading sold 25,795 Arcutis Biotherapeutics shares in Q2 2024, an estimated $233K.
  • Simplex Trading first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 7 quarters.
  • Simplex Trading's Arcutis Biotherapeutics position peaked at $361K in Q2 2022.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Simplex Trading's 13F filing for Q2 2024, filed 25 Jul 2024.